Rossmore Private Capital Buys 2,122 Shares of Stryker Corporation $SYK

Rossmore Private Capital lifted its stake in shares of Stryker Corporation (NYSE:SYK) by 12.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 19,561 shares of the medical technology company’s stock after purchasing an additional 2,122 shares during the quarter. Rossmore Private Capital’s holdings in Stryker were worth $6,892,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in Stryker by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock worth $11,917,396,000 after acquiring an additional 133,892 shares during the last quarter. Alliancebernstein L.P. increased its stake in Stryker by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after acquiring an additional 741,542 shares during the last quarter. Legal & General Group Plc increased its stake in Stryker by 4.4% in the 3rd quarter. Legal & General Group Plc now owns 2,303,290 shares of the medical technology company’s stock worth $851,457,000 after acquiring an additional 96,662 shares during the last quarter. Corient Private Wealth LLC increased its stake in Stryker by 104.4% in the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after acquiring an additional 1,146,998 shares during the last quarter. Finally, Invesco Ltd. increased its stake in Stryker by 4.5% in the 3rd quarter. Invesco Ltd. now owns 1,864,918 shares of the medical technology company’s stock worth $689,404,000 after acquiring an additional 80,536 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Price Performance

Shares of Stryker stock opened at $306.74 on Monday. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $117.59 billion, a PE ratio of 35.50, a price-to-earnings-growth ratio of 1.93 and a beta of 0.80. The business’s 50-day moving average price is $329.68 and its 200-day moving average price is $351.50. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the previous year, the business earned $2.84 earnings per share. Stryker’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts forecast that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Insider Transactions at Stryker

In related news, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares in the company, valued at $3,728,937.45. This trade represents a 28.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Canaccord Genuity Group decreased their target price on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Jefferies Financial Group restated a “buy” rating and issued a $465.00 target price on shares of Stryker in a research note on Wednesday, March 4th. Needham & Company LLC decreased their target price on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Leerink Partners assumed coverage on Stryker in a research note on Monday, April 13th. They issued an “outperform” rating and a $410.00 target price on the stock. Finally, William Blair restated an “outperform” rating on shares of Stryker in a research note on Thursday, March 5th. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $395.48.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.